Programme

WEDNESDAY 24 October 2018

12.30 – 13.15: Registration and lunch
13.15 Welcome: Ewa Rajpert-De Meyts

13.30 – 15.15: Pathology and epidemiology of testicular germ cell cancer
Chairpersons: Wolter Oosterhuis and Katherine McGlynn

13.30. Daniel Berney (London, UK): What is new in the latest WHO classification of testicular tumours and what else needs to be changed?
14.00. Andreas Stang (Essen, DE): Incidence of testicular cancer in Germany according to WHO. (short presentation)
14.15. Ariana Znaor (Lyon, FR): Predicting the testicular cancer incidence burden in Europe to 2035
14.45. Jason K. Gurney (Wellington, NZ): Unexpected features of the epidemiology of testicular cancer among different populations in New Zealand

15.15-15.45: Coffee/tea break

15.45 – 17.15: Genetic predisposition to testicular germ cell tumours
Chairpersons: Peter Kanetsky and Rolf Skotheim

15.45. Katherine McGlynn (Bethesda, MD, USA): International trends in the incidence of testicular cancer: are we close to an explanation of ethnic differences?
16.15. Kate Nathanson (Philadelphia, PA, USA): Novel testicular cancer predisposition loci begin to reveal possible mechanisms
16.45. Maria Santa Rocca (Padua, Italy): Association between copy number variations and risk of testicular cancer

17.15-17.30: Short break

17.30 – 19.00: Developmental pathways implicated in the pathogenesis of human germ cell malignancy
Chairpersons: Kate Loveland and Jason Heaney

17.30. Walfred Tang (Cambridge, UK): Epigenetic dysregulation of primordial germ cells and gonocytes as a mechanism of transformation to germ cell neoplasia in situ
18.00. Anne Jørgensen (Copenhagen, DK): The involvement of NODAL/Activin pathway in testicular dysgenesis and dysregulation of pluripotency in human fetal germ cells
18.30. Rod Mitchell (Edinburgh, UK): Modelling endocrine disruption and disorders of sex development in human fetal testis

19.00-21.00: Welcome reception
THURSDAY 25 October 2018

09.00 – 10.30: Disruption of meiosis in the pathogenesis of germ cell cancer
Chairpersons: Anne Jørgensen and Jim Amatruda

9.00. Ramsay J. McFarlane (Bangor, Wales, UK): Meiosis-like functions in oncogenesis
9.30. Aspasia Ploubidou (Jena, Germany): Spindle misorientation in the aetiology of germ cell disorders, hypofertility and testicular germ cell cancer
10.00. Anne Goriely (Oxford, UK): Spermatocytic tumours: what can this rare TGCT teach us about the fundamental processes operating in the adult male germline?

10.30-11.00: Coffee/tea break

11.00 - 13.00: Animal models and novel pathways implicated in the pathogenesis of germ cell cancer
Chairpersons: Rod Mitchell and Walfred Tang

11.00. Jason Heaney (Houston, TX, USA): Developmental origins and genetic risk factors of testicular germ cell tumors in mice
11.30. Robert S. Weiss (New York, NY, USA): A mouse model of malignant testicular cancer based on KRAS activation and PTEN inactivation
12.00. Joanna Selfe (London, UK): IGF1R signalling in primordial germ cells and testicular cancer
12.30. Trine B. Haugen (Oslo, NO): SPRY4 and SPRY4-IT1 as possible oncogenes in TGCT

13.00 - 14.45: POSTER SESSION and lunch

14.45 - 16.30: Genomic and epigenetic changes in germ cell tumours
Chairpersons: Kristian Almstrup and Kate Nathanson

14.45. Hubert Schorle (Bonn, Germany): The plasticity of germ cell cancer and its dependence on the cellular microenvironment
15.30. Leendert H. Looijenga (Rotterdam, NL): Clinical relevance of (epi)genetic changes during reprogramming of GCNIS/seminoma to nonseminomas
16.00. Louise Pyle (Philadelphia, PA, USA): Genomic changes in testicular germ cell tumors revealed by genome sequencing
16.30. Chey Loveday (Sutton, UK): Large-scale exome sequencing study of TGCT patients and controls. (short presentation)

16.45-17.15: Coffee/tea break

17.15-18.15: Immunological aspects of testicular germ cell tumours
Chairpersons: Ewa Rajpert-De Meyts and Jonathan Shamash

17.15. Kate Loveland (Clayton, VIC, AU): The contributions of cytokines to immune cell identities and functions in testicular germ cell tumours
17.45. Michal Chovanec (Bratislava, SK): Immune mechanisms and possible immune therapy in testicular germ cell tumours.
FRIDAY 26 October 2018

8.45-10.00: Paediatric germ cell tumours: special risk groups, genomics and management  
Chairpersons: Jenny Poynter and Louisa Pyle

8.45. Ewa Rajpert-De Meyts (Copenhagen, Denmark): Risk of germ cell neoplasia in sex chromosome aneuploidy  
9.00. Leendert Looijenga (Rotterdam, NL): Risk of germ cell cancer in the androgen insensitivity syndrome  
9.20. James Amatruda (Dallas, TX, USA): Genomics of paediatric germ cell tumours  
9.50. Lindsay Frazier (Boston, MA, USA): The Malignant Germ Cell International Consortium: Breaking down barriers to design the clinical and scientific agenda for pediatric and adolescent/young adult GCT patients

10.20-10.45: Coffee break

10.45-12.35: Diagnosis of GCNIS and risk classification of overt tumours  
Chairpersons: Leendert Looijenga and Carsten Bokemeyer

10.45. Kristian Almstrup (Copenhagen, DK): Detection of GCNIS in semen samples – the past, the present and the future  
11.05. Klaus-Peter Dieckmann (Hamburg, DE): Detection of GCNIS using specific miRNA profiles  
11.35. Gedske Daugaard (Copenhagen, DK): Risk factors predicting relapse of stage I testicular cancer undergoing surveillance  
12.00. Joerg Beyer (Bern, CH): Risk classification in patients with disseminated disease  
12.30. Solveig Abildtrup Larsen (Aarhus, DK): MRI with DW imaging for follow-up of patients treated for TC stage 1. (short presentation)

12.45-13.45: POSTER SESSION and lunch

13.45-15.30: Management of testicular cancer resistant to treatment  
Chairpersons: Gedske Daugaard and Jörg Beyer

13.45. Robert Hamilton (Toronto, Canada): Surgical treatment of disseminated GCTs – what is new and why?  
14.15. Carsten Bokemeyer (Hamburg, DE): Clinical features and current treatment of refractory germ cell tumours  
14.45. Christoph Oing (Hamburg, DE): Molecular basis of treatment resistance and potential therapeutic targets

15.15-15.45: Coffee break

15.45-17.30: Management of late effects in testicular cancer survivors  
Chairpersons: Niels Jørgensen and Mikael Rørth

15.45. Jourik A. Gietema (Groningen, NL): Genetic susceptibility to late effects of chemotherapy in TGCT survivors  
16.15. Mikkel Bandak (Copenhagen, DK): Testosterone deficiency in testicular cancer survivors – current evidence and future directions  
17.20. Concluding remarks and closure

Conference Dinner (19.00-24.00)
SATURDAY 27 October 2018

9.00 – 13.00 Testicular Cancer Consortium (TECAC) meeting
(for registered members only: location, entrance 4, 7. floor, conference room 4074)